1. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

    Canadian Medical Association Journal 184(10):1143 (2012) PMID 22586334 PMCID PMC3394820

    Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. We conducted a placebo-controlled, crossover trial involving adult patients with multiple sclerosis and spasticity. We recruited pa...
  2. Incidence of new-onset seizures in mild to moderate Alzheimer disease.

    Archives of Neurology 69(3):368 (2012) PMID 22410444 PMCID PMC3622046

    To estimate the incidence rate and predictors of seizures in patients with mild to moderate Alzheimer disease (AD). Cohort study of patients with mild to moderate AD in clinical trials. Risk factors for potential seizures were evaluated by stratified descriptive statistics and univariable and mu...
  3. Birth outcomes in women who have taken leflunomide during pregnancy.

    Arthritis & Rheumatism 62(5):1494 (2010) PMID 20131283 PMCID PMC3633589

    In preclinical reproductive studies, leflunomide was found to be embryotoxic and teratogenic. Women treated with leflunomide are advised to avoid pregnancy; those who become pregnant are advised to reduce fetal exposure through a cholestyramine drug elimination procedure. The present study was u...
  4. Sample size requirements for training to a kappa agreement criterion on clinical dementia ratings.

    Alzheimer Disease and Associated Disorders 24(3):264 (2010) PMID 20473138 PMCID PMC2924444

    The Clinical Dementia Rating (CDR) is a valid and reliable global measure of dementia severity. Diagnosis and transition across stages hinge on its consistent administration. Reports of CDR ratings reliability have been based on 1 or 2 test cases at each severity level; agreement (kappa) statist...
  5. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

    JAMA 300(15):1774 (2008) PMID 18854539 PMCID PMC2684821

    Blood levels of homocysteine may be increased in Alzheimer disease (AD) and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Even in the absence of vitamin deficiency, homocysteine levels can be reduced by administration of high-dose su...
  6. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.

    Neurobiology of Aging 29(9):1285 (2008) PMID 17452062 PMCID PMC2768818

    The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate m...
  7. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

    Neurobiology of Aging 29(9):1285 (2008)

    The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate r...
  8. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.

    Archives of Neurology 64(1):108 (2007) PMID 17210817

    Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician. To assess the ad...
  9. S3-02-01:ADCS homocysteine trial

    Alzheimer's & Dementia 3(3):S199 (2007)

  10. Depressed mood in informal caregivers of individuals with mild cognitive impairment.

    American Journal of Alzheimer's Disease and Oth... 22(4):273 (2007) PMID 17712158

    This study estimates the prevalence of depressed mood in caregivers of individuals with mild cognitive impairment (MCI) and assesses whether demographics, stressors, intrapsychic strain, and gain are associated with depressed mood. A secondary analysis of baseline data from the Alzheimer's Disea...
  11. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.

    Alzheimer Disease and Associated Disorders 20(4 Suppl 3):S191 (2006) PMID 17135812 PMCID PMC3229195

    The Prevention Instrument project of the Alzheimer's Disease Cooperative Study (ADCS) seeks to develop instruments to assess treatment efficacy including potential economic benefit. The Resource Use Inventory (RUI) is an instrument that has been used to capture resource utilization and costs in ...
  12. O4-04-07:Treatment of mild cognitive impairment with vitamin E and donepezil: Correlation between rates of change on MRI and cognitive/behavioral measures

    Alzheimer's & Dementia 2(3):S84 (2006)

  13. IC-P-096:Treatment of mild cognitive impairment with vitamin E and donepezil: Correlations between serial MRI and conversion, genotype, and treatment status

    Alzheimer's & Dementia 2(3):S691 (2006)

  14. ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials.

    Alzheimer Disease and Associated Disorders 20(4 Suppl 3):S139 (2006) PMID 17135807

    The validity and reliability of clinic-based and telephone-based versions of a 4 word delayed recall test were evaluated in nondemented elderly individuals (n=644) participating in a simulated primary prevention clinical trial. There was no significant difference in the average scores achieved b...
  15. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials.

    Alzheimer Disease and Associated Disorders 20(4):232 (2006) PMID 17132967 PMCID PMC3526370

    To evaluate the feasibility of longitudinal assessment and the psychometric properties of both established and new outcome measures used in clinical trials of patients with dementia in a cohort of Spanish-speaking elders in the United States. This is a prospectively collected multicenter study c...
  16. P4-231:Depressive mood in family caregivers of persons with mild cognitive impairment

    Alzheimer's & Dementia 2(3):S584 (2006)

  17. P2-186:Treatment of mild cognitive impairment with vitamin E and donepezil: Correlations between serial MRI and conversion, genotype, and treatment status

    Alzheimer's & Dementia 2(3):S289 (2006)

  18. Vitamin E and donepezil for the treatment of mild cognitive impairment.

    New England Journal of Medicine 352(23):2379 (2005) PMID 15829527

    Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease. In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E da...
  19. Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer’s disease: A hazard-ratio analysis

    Alzheimer's & Dementia 1(1):S93 (2005)

  20. P1-003 ADCS Prevention instrument project: assessment of activities of daily living (ADL)

    Neurobiology of Aging 25:S94 (2004)